Updates are available Correction dated 2025-08-30
Click to view Correction: https://doi.org/10.1007/s40121-025-01226-y
-
Authors
Chuo, Ching-Yi https://orcid.org/0000-0003-4255-9649
Zachry, Woodie
de Boer, Melanie
Telep, Laura
Tao, Li
-
Funding
Funding for this research was provided by:
Gilead Sciences, Inc.
- License Information
-
More Information
Article History
Received: 18 April 2025
Accepted: 26 June 2025
First Online: 15 July 2025
Change Date: 30 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40121-025-01226-y
Declarations
:
: Ching-Yi Chuo, Woodie Zachry, Laura Telep, and Li Tao are employees and stockholders of Gilead Sciences, Inc. Melanie de Boer is a former employee and stockholder of Gilead Sciences, Inc.
: As this study involved secondary data use of de-identified administrative claims data, institutional review board or independent ethics committee review was not required. The patient identifiers in all data sources were removed, and the data contained no patient identifiable fields. No informed consent was obtained to participate in this secondary analysis of existing data. However, informed consent may have been granted when the original study data were collected. This study was conducted according to the Good Pharmacoepidemiology Practice and in line with the relevant Modules of the Heads of Medicines Agencies Good Pharmacovigilance Practices.
